{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04931368\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["MATRix"]],"indication":"newly diagnosed primary CNS lymphoma","name":"OptiMATe","nct_id":"NCT04931368","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=optimate-nct04931368. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OptiMATe","arms":[{"description":"Patients receive four courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) as induction treatment. Response assessment with gadolinium-enhanced brain MRI (centrally reviewed) takes place after course two and four. Patient with at least PR proceed to 3rd course of MATRix after first response assessment and to HCT-ASCT (BCNU 400 mg/m2, Thiotepa 4 x 5 mg/kg; i.v.) after second response assessment. Collection of autologous stem cells is planed after the second course of MATRix.","label":"Control treatment (Arm A)","type":"ACTIVE_COMPARATOR"},{"description":"As induction treatment, patients receive one course of Rituximab/HD-Methotrexate (Rituximab 375 mg/m2, HD-Methotrexate 3.5 g/m2; i.v.). In the absence of clinical signs of progression, patients proceed to two courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) followed by a response assessment with gadolinium-enhanced brain MRI (centrally reviewed). Patients with at least PR will proceed to HCT-ASCT (BCNU 400 mg/m2, thiotepa 4 x 5 mg/kg; i.v.). Collection of autologous stem cells is planed after the first course of MATRix","label":"Experimental treatment (Arm B)","type":"EXPERIMENTAL"}],"collaborators":["German Federal Ministry of Education and Research","University Hospital Freiburg"],"completion_date":{"date":"2028-11","type":"ESTIMATED"},"conditions":["Primary Central Nervous System Lymphoma"],"enrollment":{"count":331,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix","otherNames":[],"type":"DRUG"},{"name":"Control intervention: four courses of MATRix","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-18","lead_sponsor":"Klinikum Stuttgart","official_title":"Optimizing MATRix as Remission Induction in PCNSL: De-escalated Induction Treatment in Newly Diagnosed Primary CNS Lymphoma - a Randomized Phase III Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free survival (EFS)","timeFrame":"up to 24 months after end of treatment"}],"references":[],"start_date":{"date":"2021-06-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma","url":"https://clinicaltrials.gov/study/NCT04931368"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/optimate-nct04931368"}